Corxel Pharmaceuticals is catching up to others with oral GLP-1 obesity drugs, but the biotech claims its small molecule could offer better tolerability compared to the rest of its class. The SPAC merger taking Corxel public is expected to close in the first half of 2027, which is when the biotech plans to start a Phase 3 trial.
We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.
